A Phase I, Randomized, Investigator/Participant-blind, Parallel-group, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants
Latest Information Update: 05 Jan 2026
At a glance
- Drugs RO 7806881 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 30 Dec 2025 Status changed from not yet recruiting to recruiting.
- 15 Dec 2025 New trial record